We’ve decided to get a couple of off-label use-related items off of our to-do-eventually list today. The first we’ve alluded to already. It’s the First Amendment litigation that Allergan recently commenced against the FDA involving the truthful “promotion” of off-label use (specifically use of Botox to treat muscle spasticity). The second is a new law review article on off-label use: R. Dresser & J. Frader, “Off-Label Prescribing: (more…)

If you are interested in advertising here, please use the links below for more information.
Advertising spots are located in either the right hand column or at the bottom of the site. Also, if there is something of public interest you feel I should include, please let me know as well. I try to bring articles of both current interest and perhaps items you may not find easily relative to healthcare on the web, to keep it interesting.
Recently (more…)

and Teva have announced and even made some early investments.  Bio-Similars appear to have the makings of the next “generic” type of drug, not completely generic, but a drug with the same outcome at a cheaper price.  In other news today the company announced the elimination of 900 positions, mostly sales. 
yet.  BD 
WASHINGTON -(Dow Jones)- A Johnson & Johnson (JNJ) policy director on Tuesday said the health-care conglomerate (more…)